RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

12.05.2022 - First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 ...

Related Keywords

United States ,America ,Lisam Wilson ,Brian Markison ,Exchange Commission ,Site Communications Inc ,Alora Pharmaceuticals ,Adamas Pharmaceuticals Inc ,Nasdaq ,Annual Beauty Awards ,Sandow Publication ,Professional Treatment ,Shape Healthy Beauty ,Chief Executive Officer ,Shape Magazine ,Direct Dispense ,License Agreement ,Annual Report ,Media Relations ,Site Communications ,Financial Tables ,Condensed Consolidated Statements ,Months Ended March ,Operating Activities ,Investing Activities ,Financing Activities ,Note Purchase Agreement ,Adamas Pharmaceuticals ,